X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: New era of medicine initiative kicks off in Boston

By Andrew Powaleny  |    February 22, 2017
It’s no secret that Boston, Massachusetts is home to many of the most groundbreaking advancements in medical discovery. That’s why yesterday, PhRMA sponsored its first national health care...   Read More

Exploring the new era of medicine

By Bill Chin, M.D.  |    February 21, 2017
We are in a new era of medicine where innovations are transforming our ability to attack the cause of disease, not just the symptoms. Where treatment decisions are increasingly focused on the...   Read More

Significant progress fighting cancer: Death rate has dropped 25 percent

By Holly Campbell  |    January 9, 2017
Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate...   Read More

New report provides recommendations for securing and protecting IP

By Mark Grayson  |    December 13, 2016
This week, the White House Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC) issued a Joint Strategic Plan outlining actions government, industry, educational institutions...   Read More

New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

By Hannah Mooney  |    November 14, 2016
Today, there are more than 30 million Americans suffering from type 1 or type 2 diabetes. Roughly 5 percent of patients have type 1 and 90 to 95 percent suffer from type 2, highlighting the...   Read More

New report highlights need to speed patent examination

By Mark Grayson  |    November 2, 2016
The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent...   Read More

Study highlights negative impact of Canada's promise doctrine on R and D investment

By Mark Grayson  |    October 21, 2016
A newly published study from Charles River Associates (CRA) has found that Canada’s approach to intellectual property (IP), innovation and patient care is being jeopardized because of its adoption...   Read More

New report highlights impact of intellectual property on U.S. economy

By Mark Grayson  |    October 13, 2016
In late September, the U.S. Department of Commerce released a comprehensive report that found intellectual property (IP) intensive industries contribute more than $6 trillion (38.2 percent) to...   Read More

4 recommendations for ICER

By Lauren Neves  |    September 26, 2016
For years, PhRMA has supported policies that ensure health care decisions are grounded in the best available evidence. In our policy solutions for delivering innovative treatments to patients...   Read More

2016 BCI Survey: A pro-innovation environment is essential for biopharmaceutical investment

By Guest Contributor  |    September 16, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates